STOCK TITAN

Niki BioSolutions COO receives 80,000 stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Niki BioSolutions, Inc. President & COO Alidad Mireskandari received 20,000 restricted stock units that vested on July 22, 2026, and reported 20,000 common shares following the transaction. He also received 80,000 stock options with an $8.83 exercise price, expiring July 22, 2036. The options vest through quarterly installments and specified milestones tied to revenue, financing, agreements, a clinical validation study, and stock-price performance.

Insider Mireskandari Alidad
Role President & COO
Type Security Shares Price Value
Grant/Award Restricted Stock Units F1, F2 20,000 $0.00 $0.00
Grant/Award Stock Options F3 80,000 $0.00 $0.00
Exercise Common Stock F1 20,000 -- --
Holdings After Transaction: Restricted Stock Units — 0 units (Direct); Stock Options — 80,000 options (Direct); Common Stock — 20,000 shares (Direct)
Holdings Before and After: Restricted Stock Units, 20,000 to 0 units (Direct); Stock Options, 0 to 80,000 options (Direct); Common Stock, 0 to 20,000 shares (Direct)
Footnotes (3)
  1. F1. Each RSU represents a contingent right to receive, upon settlement, one share of Common Stock.
  2. F2. On July 22, 2026, the reporting person was granted 20,000 RSUs, which vested on that same date.
  3. F3. The options vest as follows: (i) 40,000 options vest in eight equal quarterly installments; (ii) 5,000 options vest upon completion and publication of the clinical validation study of CogniMIR(R) to meet CLIA requirements; (iii) 10,000 options vest upon the Company entering into a biopharmaceutical services, collaboration or partnership agreement resulting in proceeds to the Company of at least $250,000; (iv) 5,000 options vest upon the Company generating $1,000,000 in revenue; (v) 10,000 options vest upon completion of capital raises totaling $5,000,000; and (vi) 10,000 options vest upon a 100% increase in the Company's stock price following the closing of the merger that occurred in July 2026.
Restricted stock units granted 20,000 RSUs Granted and vested July 22, 2026
Common shares following transaction 20,000 shares Direct holdings reported after the July 22, 2026 transaction
Stock options granted 80,000 options Grant reported July 22, 2026
Option exercise price $8.83 per share For the stock options granted July 22, 2026
Option expiration date July 22, 2036 Expiration date of the granted stock options
Agreement proceeds vesting threshold at least $250,000 Options vest upon a qualifying agreement resulting in proceeds to the company at this level
Revenue vesting threshold $1,000,000 Options vest upon the company generating this revenue
Capital raises vesting threshold $5,000,000 Options vest upon completion of capital raises totaling this amount
RSU technical
"Each RSU represents a contingent right to receive, upon settlement, one share"
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
stock options financial
"The options vest as follows"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vest technical
"40,000 options vest in eight equal quarterly installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
clinical validation study medical
"completion and publication of the clinical validation study of CogniMIR(R)"
A clinical validation study tests a medical test, device, drug, or treatment in real people to confirm it measures or works as intended, usually comparing results to a trusted standard. Think of it like a road test that shows whether a new tool performs reliably in real-world settings. For investors, results affect regulatory approval, market acceptance and commercial potential because successful validation reduces uncertainty about safety, accuracy and usefulness.
CLIA requirements regulatory
"to meet CLIA requirements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did NIKI's President & COO receive?

Alidad Mireskandari, Niki BioSolutions' President & COO, received 20,000 restricted stock units that vested on July 22, 2026, and 80,000 stock options with an $8.83 exercise price. The options expire July 22, 2036.

How do the NIKI stock options vest?

The options vest in 40,000 options in eight equal quarterly installments, with the remainder tied to milestones: 5,000 upon completion and publication of the CogniMIR(R) clinical validation study to meet CLIA requirements; 10,000 upon a qualifying agreement resulting in at least $250,000 in proceeds to the company; 5,000 upon $1,000,000 in revenue; 10,000 upon capital raises totaling $5,000,000; and 10,000 upon a 100% increase in the company's stock price following the July 2026 merger closing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mireskandari Alidad

(Last)(First)(Middle)
116 VILLAGE BOULEVARD, SUITE 200

(Street)
PRINCETON NEW JERSEY 08540

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Niki BioSolutions, Inc. [ NIKI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President & COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/22/2026M20,000A(1)20,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)07/22/2026A20,000 (2) (2)Common Stock20,000$00D
Stock Options$8.8307/22/2026A80,000 (3)07/22/2036Common Stock80,000$080,000D
Explanation of Responses:
1. Each RSU represents a contingent right to receive, upon settlement, one share of Common Stock.
2. On July 22, 2026, the reporting person was granted 20,000 RSUs, which vested on that same date.
3. The options vest as follows: (i) 40,000 options vest in eight equal quarterly installments; (ii) 5,000 options vest upon completion and publication of the clinical validation study of CogniMIR(R) to meet CLIA requirements; (iii) 10,000 options vest upon the Company entering into a biopharmaceutical services, collaboration or partnership agreement resulting in proceeds to the Company of at least $250,000; (iv) 5,000 options vest upon the Company generating $1,000,000 in revenue; (v) 10,000 options vest upon completion of capital raises totaling $5,000,000; and (vi) 10,000 options vest upon a 100% increase in the Company's stock price following the closing of the merger that occurred in July 2026.
/s/ Alidad Mireskandari11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading